ArticlePLOS global public health2026
Feasibility and acceptability of hepatitis C virus self-testing models among high-risk groups in Nasarawa, Nigeria; Exploratory cross-sectional analysis of an implementation study.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) infection remains a major public health challenge, with significant gaps in diagnosis and treatment in resource-limited settings. Hepatitis C self-testing (HCVST) offers a potential strategy to expand access, particularly in HIV clinical settings. We evaluated feasibility and acceptability of HCVST among high-risk populations in Nasarawa State, Nigeria when provided at antiretroviral (ART) clinics and one-stop shops (OSS) serving key populations (KP). 2,000 participants were enrolled between May 2023 and December 2023. Participants tested with either finger-prick blood-based or oral fluid antibody HCVST, and with or without health worker support. Follow-up documented results and linkage to qualitative RNA PCR confirmatory testing and treatment. Case-complete feasibility analyses were conducted across the HCV care cascade using chi-square tests (N = 1995). Acceptability was evaluated using a post-test survey score derived through case-complete factor analysis (N = 1868); associations between lowest decile acceptability score and participant characteristics were explored through regression analyses. Outcomes were compared by facility type (ART clinic vs. OSS). Free-text responses were thematically analyzed to contextualize findings. HCVST was feasible and acceptable. Of 226 reactive HCVST results (11.3%), 99.1% received RNA PCR testing. Among those with detectable RNA, 92% initiated treatment and 97% completed therapy. However, differences were observed by facility type. Participants in ART clinics were older, more likely to be female, and showed higher reactivity (15% vs. 8%) and treatment uptake (96% vs. 83%) than OSS clients. Acceptability was higher in ART clinics than OSS. HCVST was both feasible and acceptable in Nasarawa State, with some observed variations by facility type. These findings suggest that with differentiated service delivery models and adequate support for linkage, HCVST can increase HCV diagnosis, linkage to care, and treatment among high-risk groups in Nigeria, supporting integration of HCVST into national viral hepatitis elimination strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.